Jun 15,2020

One Drop Announces Long-term Outcomes Forecasts for Diabetes-related Biomarkers and Overnight Hypoglycemia Predictions for CGM Users

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented long-term A1C, blood pressure, and weight outcomes forecasts for individuals, along with overnight hypoglycemia predictions for CGM users at the 80th Annual American Diabetes Association Virtual Scientific Sessions. New predictions lay the foundation for One Drop’s highly personalized and adaptive data-driven health products.

CLINICAL STUDY

#software

View Analyst & Ambassador Comments
Go to original news
Jun 23,2020

Akili Announces CE Mark Approval of EndeavorRx™ Digital Treatment for Children with ADHD

Akili today announced that it has received Conformité Européenne (CE) Mark certification for EndeavorRx (AKL-T01), as a prescription-only digital therapeutic software intended for the treatment of attention and inhibitory control deficits in pediatric patients with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is one of the most common psychiatric disorders in childhood and nearly 5 percent of children in Europe are diagnosed with the disorder.

REGULATORY CE MARK

#pdt

#software

View Analyst & Ambassador Comments
Go to original news
Jul 08,2020

Braingaze partners with Ping An, 7invensun to deliver ADHD diagnostic solutions in China

Barcelona, Spain-based digital therapeutic company Braingaze announced that it is partnering with China’s insurance giant Ping An Group and eye-tracking innovator 7invensun to deliver convenient and accurate diagnostic solutions to kids in China who are suffering from ADHD disorders. As part of a broader collaboration with Ping An Group, the health services giant in China, Braingaze set out to explore how these diagnostic testing solutions could be offered to Chinese clinicians which run into possible cases of ADHD.

COLLABORATION PARTNERSHIP

#r&d

#software

View Analyst & Ambassador Comments
Go to original news
Aug 24,2020

Ehave Announces Plans to Accelerate the Monetization of Its Proprietary Digital Health Platform

Ehave, Inc., a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced it is accelerating plans to monetize its Ehave Dashboard. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals. The Ehave Dashboard is expected to be available sometime in the fourth quarter.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Aug 26,2020

Ehave to Release Doctors Dictation – An AI Powered Video and Voice Analysis Module

Ehave, Inc., a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced the release of Doctors Dictation, an artificial intelligence (AI) powered video and voice analysis module, as part of the Ehave Dashboard. Ehave Doctors Dictation is an AI powered video and voice analysis module that combines text, audio, and video to manage and understand information. Doctors or practitioners can spend more time speaking to their patients instead of focusing on taking notes.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Sep 08,2020

Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that it has been granted a CE mark for its Nerivio® device for acute treatment of migraine, a little more than a year after receiving FDA clearance in the United States. This milestone allows the award-winning wearable therapeutic device to be marketed in select countries in Europe, as part of the company's roll-out plan, starting in 2021

REGULATORY CE MARK

#software

#connected device

View Analyst & Ambassador Comments
Go to original news
Sep 11,2020

Medisafe Launches New Platform for Medication Management to Improve Patient Journey

Medisafe, a Boston, MA-based digital therapeutics companion platform, announced the immediate deployment of its new Medisafe Maestro platform. Medisafe Maestro fosters collaboration with partners to build adaptive patient journeys that address individual challenges, providing personalized support to navigate through any roadblocks to continue treatment.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Sep 16,2020

Health2Sync partners with Sanofi to deliver a digital solution for diabetes patients & care providers

Taiwan-based digital health startup Health2Sync has entered into a partnership with pharma giant Sanofi with the aim to apply the digital solution provided by Health2Sync in 300 clinics and hospitals nationwide certified by Taiwan Diabetes Shared Care Network over the next three years. As part of the partnership, Health2Sync will provide patient management software for healthcare professionals and a mobile app for patients in 300 Sanofi-contracted clinics and hospitals, to realize an integrated and digitized diabetes management.

COLLABORATION PARTNERSHIP

#r&d

#software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 01,2020

BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence

BIOCORP, a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions. This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.''

COLLABORATION PARTNERSHIP

#connected device

#software

View Analyst & Ambassador Comments
Go to original news
Oct 06,2020

Voluntis Announces Issuance of US Patent for the Proprietary Algorithm Engine of Theraxium

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a leader in digital therapeutics, announces today the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering the clinical algorithm engine of the Theraxium platform and the unique process developed by Voluntis for designing patient decision support and self-management algorithms.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Subscribe to SOFTWARE